Skip to main content
. 2022 Nov 3;14(11):2370. doi: 10.3390/pharmaceutics14112370

Figure 2.

Figure 2

Application of the CRISPR/Cas system for the development of biotherapeutic tools against infections crossing the BBB. (A) Lactobacillus expression host, (B) CRISPR/Cas expression vector, (C) expression of the engineered vector in Lactobacillus, (D) CRISPR/Cas-enriched Lactobacillus bEV, and (E) targeted therapy against pathogenic bacteria via surface protein receptors. The figure was created using BioRender.com (https://app.biorender.com; accessed on 2 November 2022).